Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) EBITDA (2023 - 2025)

Mereo BioPharma (MREO) has disclosed EBITDA for 3 consecutive years, with -$7.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 50.89% to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.9 million through Dec 2025, up 24.13% year-over-year, with the annual reading at -$33.9 million for FY2025, 24.13% up from the prior year.
  • EBITDA for Q4 2025 was -$7.3 million at Mereo BioPharma, up from -$9.3 million in the prior quarter.
  • The five-year high for EBITDA was -$351000.0 in Q2 2023, with the low at -$14.8 million in Q4 2024.
  • Average EBITDA over 3 years is -$8.6 million, with a median of -$9.3 million recorded in 2025.
  • The sharpest move saw EBITDA tumbled 3390.03% in 2024, then skyrocketed 50.89% in 2025.
  • Over 3 years, EBITDA stood at -$5.0 million in 2023, then tumbled by 195.47% to -$14.8 million in 2024, then surged by 50.89% to -$7.3 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$7.3 million, -$9.3 million, and -$8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.